As a result, it appears that saroglitazar, a dual PPARα/γ agonist, may be useful in the prevention or treatment of NAFLD. On the other hand, the anti-oxidant and anti-inflammatory properties of flavonoids make them effective in inhibiting free radicals and other unstable molecules. Here, PPARA is linked to metabolic dysfunction-associated steatotic liver disease.